1. NRG Oncology Biospecimen Bank Report NRG Semiannual meeting
General Session
Richard Jordan DDS PhD FRCPath
Nilsa Ramirez, MD
Peter Lucas, MD, PhD
Jeffry Simko, MD, PhD
NRG Semiannual meeting
Phoenix February 2019

3. NRG Oncology Open Trials
Open Trials on January 20, 2019
Disease Site
# Trials
Target Accrual
Accrued Cases GU 4
4,407
2,791
Breast 5
5,786
2,384
GYN 11
3,669
2,090
H&N
1,721
752
Brain
972
670 GI
1,023
466
Lung
870
350
Sarcoma 1 46
Totals 37
18,494
9,503

4. NRGBB Inventory NRGBB Year 4 TOTALS
Total Cases (Patients) with Biospecimens
233,376
Total Biospecimens
2,733,234
Total Cases (Patients) Received Years 1-4
12,217
Total Biospecimens Received Years 1-4
230,468
Total Biospecimens Distributed Years 1-4
78,761

5. NRGBB Years 1-4 (2015-2018) Biospecimen Distributions by Organ Site
Disease Site
# Trials
# Specimens
# Patients
GYN 22
41,948
3,982
Breast 5
14,076
10,564
Brain 10
7,839
1,685 GU 8
7,752
1,024 GI 4
4,189
520
H&N 7
2,957
970
TOTALS for NRG 56
78,761
18,745

6. Data uploaded into NCI-Navigator January 2019
Lead Group
Trials
Specimens
NRG-O 47
474,655
Alliance 30
149,388
SWOG 17
80,202
ECOG-ACRIN 16
46,204
TOTAL
110
750,449

7. four Cancer Immune Monitoring and Analysis Centers (CIMACs)
Dana-Farber Cancer Institute, Stanford University, MD Anderson, and Mount Sinai, 
analyses for genomic, phenotypic and functional characterization of responses of patients in early phase clinical trials

8. CIMAC Trials and NRG Oncology
$600K U24 Supplement for Year 4 awarded to NRG in October. Ends March
Supplement for extra costs related to Navigator, special tubes, other studies/costs not funded by original U24 RFA.
NRGBB agreed to change priority of funding to CIMAC costs first
NCE will be requested as needed.
ONE trial is now active- LU004.
3 concepts being discussed.